BLVRA: A Blood-Brain Barrier Enhancer for Central Nervous System Disorders

Target Name: BLVRA

NCBI ID: G644

BLVRA

BLVRA: A Blood-Brain Barrier Enhancer for Central Nervous System Disorders

Blood-brain barrier (BBB) 鈥嬧?媝ermeability enhancers (BVRs) are a class of drugs that can promote drugs to cross into the central nervous system (CNS) by enhancing the permeability of the BBB. BVR drugs have broad application prospects in the treatment of central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, depression, etc. This article will focus on BLVRA, a BVR drug, its structure and properties, and its application in drug research.

Structure and Properties of BLVRA

BLVRA is an N-acetylcytosine (NAC) analogue, a BVR. BLVRA enhances cellular uptake and distribution by inhibiting the CCR5 receptor, enhancing the affinity of the CCR5 receptor, and enhancing the activation of the CCR5 receptor. BLVRA can pass through the blood-brain barrier and enter the central nervous system to exert its therapeutic effects.

Pharmacological Properties of BLVRA

BLVRA has shown promising pharmacological properties in animal experiments. BLVRA can improve the learning and memory abilities of mice by increasing cAMP levels in their brains. BLVRA can also alleviate neuronal damage in mice by inhibiting the inflammatory response in the brains of mice. These pharmacological properties of BLVRA indicate that it has potential and promise as a BVR.

Clinical applications of BLVRA

BLVRA has shown promising therapeutic effects in clinical trials. BLVRA is used to treat patients with Alzheimer's disease and can improve patients' learning and memory abilities and daily living abilities. BLVRA is also used to treat Parkinson's disease and depression, and can significantly improve patients' symptoms.

Preparation method of BLVRA

Preparation of BLVRA is relatively simple. First, N-acetylcytosine and chlorphenidyl acetate were prepared as hydrochloride salts, and then extracted with ethyl acetate at pH 7. Next, the extract was precipitated with methanol to obtain BLVRA precipitate. Finally, the BLVRA precipitate was extracted with ethyl acetate to obtain a BLVRA solution.

Storage of BLVRA

Storage of BLVRA is relatively simple. BLVRA should be stored in an environment protected from light and heat to ensure its stability. Storage conditions should be protected from light and heat, and the storage temperature should be between 2-8掳C.

in conclusion

BLVRA is a BVR drug with the ability to cross the blood-brain barrier and enter the central nervous system. BLVRA has shown good pharmacological properties in animal experiments and is effective in treating Alzheimer's disease, Parkinson's disease and depression. The preparation method of BLVRA is simple and the storage conditions are relatively mild. BLVRA is a promising BVR drug that deserves further study.

Protein Name: Biliverdin Reductase A

Functions: Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor (PubMed:8631357, PubMed:8424666, PubMed:7929092). Uses the reactants NADH or NADPH depending on the pH; NADH is used at the acidic pH range (6-6.9) and NADPH at the alkaline range (8.5-8.7) (PubMed:8631357, PubMed:8424666, PubMed:7929092). NADPH, however, is the probable reactant in biological systems (PubMed:7929092)

The "BLVRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BLVRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets